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Abstract
Background: The breast cancer susceptibility gene, BRCA1, is implicated in multiple cellular processes
including DNA repair, the transactivation of genes, and the ubiquitination of proteins; however its precise
functions remain to be fully understood. Identification and characterization of BRCA1 protein interactions
may help to further elucidate the function and regulation of BRCA1. Additionally, detection of changes in
the expression levels of BRCA1 and its interacting proteins in primary human breast tumors may further
illuminate their role in the development of breast cancer.
Methods: We performed a yeast two-hybrid study to identify proteins that interact with exon11 of
BRCA1 and identified Protein Phosphatase 1β (PP1β), an isoform of the serine threonine phosphatase,
PP1. GST-pull down and co-immunoprecipitation assays were performed to further characterize this
interaction. Additionally, Real-Time PCR was utilized to determine the expression of BRCA1, PP1α, β and
γ in primary human breast tumors and normal breast tissue to identify alterations in the expression of
these genes in breast cancer.
Results: PP1 and BRCA1 co-immunoprecipitate and the region within BRCA1 as well as the specific PP1
interacting domain mediating this interaction were identified. Following mRNA expression analysis, we
identified low levels of BRCA1 and variable levels of PP1α and β in primary sporadic human breast tumors.
Furthermore, BRCA1, PP1β and PP1γ were significantly higher in normal tissue specimens (BRCA1 p =
0.01, PP1β: p = 0.03, PP1γ, p = 1.9 × 10-6) compared to sporadic breast tumor samples. Interestingly, we
also identified that ER negative tumors are associated with low levels of PP1α expression.
Conclusion: The identification and characterization of the interaction of BRCA1 with PP1 and detection
of changes in the expression of PP1 and genes encoding other BRCA1 associated proteins identifies
important genetic pathways that may be significant to breast tumorigenesis. Alterations in the expression
of genes, particularly phosphatases that operate in association with BRCA1, could negatively affect the
function of BRCA1 or BRCA1 associated proteins, contributing to the development of breast cancer.
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Background
The breast cancer susceptibility gene, BRCA1, is involved
in the development of a significant proportion of familial
breast and ovarian cancers and may also play a role in the
development of sporadic breast cancer [1,2]. The BRCA1
protein has an amino terminal RING finger domain,
potentially involved in ubiquitination, and two BRCA1 C-
terminal domains (BRCT), which interact with a number
of proteins involved in the transactivation of genes. The
central portion of BRCA1, mainly encoded by exon11,
contains two nuclear localization signals and interacts
with proteins involved in DNA repair as well as the cen-
trosomal protein, γ-tubulin [3]. Evidence suggests that
BRCA1 functions as a scaffold, coordinating DNA repair
[4], the transactivation of genes [5] and centrosome sepa-
ration or maturation [6].
The phosphorylation of BRCA1 may be important for its
function throughout the cell cycle. BRCA1 is hypophos-
phorylated during G1/S [7]; however, it becomes phos-
phorylated from S to G2/M phase. BRCA1 also interacts
with kinases involved in cell cycle control and apoptosis
such as the cyclin/cdk complexes [7], and a hypophos-
phorylated form of BRCA1 has been found at the centro-
somes during mitosis [8].
The vertebrate serine/threonine protein phosphatase,
PP1, has 3 isoforms: α, β (also known as δ) and γ that are
highly conserved across their large catalytic domain, but
are divergent at the amino- and carboxy-termini. Regula-
tory proteins bind to the unique carboxy termini of the
PP1 isoforms to direct their isoform specific activities. For
example, PP1γ knock-out mice have impaired spermio-
genesis, indicating that the other PP1 isoforms are not
entirely able to compensate for the loss of PP1γ; and the
presence of polyploid spermatids in these mice suggests a
defect in meiosis [9]. Furthermore, the PP1α isoform has
also been found to associate with BRCA1 [10].
We have used a yeast two-hybrid assay to detect proteins
that interact with exon11 of BRCA1. This large exon
encodes roughly 60% of the protein, and we wished to
identify potentially important interacting proteins outside
of the intensely studied RING and C-terminal regions of
BRCA1. The identification of PP1β as a BRCA1 interacting
protein and characterization of the interaction of BRCA1
with PP1α, β and γ both in vitro and in vivo, provides new
insights into the roles of both BRCA1 and the PP1 iso-
forms. These biochemical results led to analysis of the
expression of BRCA1 as well as PP1α, β and γ, which has
provided unique evidence for their potential deregulation
in breast cancer. Disruption of the interaction of BRCA1
with PP1, or deregulation of its expression, could result in
changes in the balance of kinase and phosphatase activi-
ties in the cell, leading to tumorigenesis.
Methods
Two-hybrid screening in yeast
Sequences from 900 to 4000 bp of BRCA1, were ligated
into the DNA binding domain (DBD) yeast expression
vector pAS1 (GAL4 (1–147) DNA-BD, TRP1, ampr). The
yeast strains pJ69-4A (MATa trp1-901, leu2-3, 112 ura3-52,
his3-200, gal4∆,  gal80∆,  LYS2::gal1-HIS3, GAL2-ADE2,
met2::GAL7-lacZ) and Y187 (MATα,  ura3-52, his3-200,
ade2-101, trp1-901, leu2-3, 112, gal4∆,  met-,  gal80∆,
URA3::GAL1UAS-GAL1TATA-lacZ) were utilized in this
study. Yeast were initially transformed with the DBD-
exon11 plasmid, followed by the Human Mammary
Gland cDNA library cloned into the pACT2 Activation
domain plasmid (Clontech). A total of 5 × 105 clones were
tested.
Co-immunoprecipitation
Coding sequences of PP1α, β or γ were ligated into the
pCMVFlag (Sigma) expression vector. HEK293T cells were
transfected with either of the PP1 vectors or the negative
control pFLagLaf4 [11]. Cells were lysed using NETN
buffer (150 mM NaCl, 1 mM EDTA, 20 mM Tris pH8.0,
0.5% NP40) along with the protease inhibitor cocktail 1
and phosphatase inhibitor cocktail 1 (Sigma); lysates
were incubated with 1 µg/ml BRCA1 Ab1 and 3 (Onco-
gene) or 1 µg/mlM2-Flag (Sigma) rotating overnight at
4°C. 25 µl of protein G-agarose beads (Santa Cruz) were
added and samples were incubated at 4°C for 2 hours.
Antibodies used for Westerns were: 1 µg/ml BRCA1 Ab1
plus 1 µg/ml Ab3 (Oncogene) or 1 µg/ml M2 Flag
(Sigma).
Construction and expression of bacterial GST fusion 
proteins
Inserts of BRCA1 were generated using HiFiTaq Polymer-
ase (Invitrogen), using the BRCA1 primers described in
Scully et al. [12]. BR-4 V-A and F-A were generated using
in vitro PCR mutagenesis [13] (Primers used were
1forward: GAAAGATCTGTAGAGAGTAGC, 1reverse (V-
A): CAAAAGTGGCTTTTG GACTTTG, 1reverse (F-A): CAT-
TCAGCAGTGACTTTTGGAC, 2forward (V-A):
CCAAAAGCCACTTTTGAATGTG, 2forward (F-A):
GTCACTGCTGAATGTGAAC, 2reverse: CCACTTCATTAG-
TACTGGAACC). pLysS bacterial cells, transformed with
the BRCA1 constructs and induced for protein expression,
were lysed using B-Per bacterial cell lysis reagent (Pierce)
plus 1 mM PMSF and DNAse (200U/ml, Invitrogen)
according to manufacturer's directions. Lysates were incu-
bated with 50 µl of a 50% GST slurry overnight at 4°C.
The amount of GST-bound protein was determined by
comparison with known amounts of BSA loaded onto the
gel, with amounts ranging from 0.1ug to 2ug of BSA.BMC Cancer 2007, 7:85 http://www.biomedcentral.com/1471-2407/7/85
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In vitro GST-interaction studies
1 µg of GST-bound protein was added to HEK293T cell
lysate (1 mg of protein per reaction), and incubated rotat-
ing at 4°C for 2 hours. GST pellets were washed 3X with 1
mL of NETN + protease and phosphatase inhibitors
(Sigma) and GST-bound proteins were eluted using SDS
PAGE loading dye. Samples were electrophoresed on a
12% SDS-PAGE gel and transferred to a nitrocellulose
membrane. Immunoblots were probed with 1 µg/ml of
the PP1 E-9 antibody (Santa Cruz) and bands were visual-
ized using a Fluor-S MultiImager (BioRad). Binding of
PP1 to BR-4 V-A or F-A was compared with binding of PP1
to wild-type BR4 in order to determine the relative degree
of interaction.
Tissue samples
Twenty-nine tumors from sporadic breast cancers were
obtained as part of a prospective study of molecular alter-
ations in auxiliary node-negative disease [14]. Following
frozen section diagnosis of invasive cancer, tumor speci-
mens were sampled by a pathologist and immediately
snap frozen and stored in liquid nitrogen. DNA and RNA
have previously been extracted from these tumors by con-
ventional techniques [15]. Normal breast mRNA was
obtained, by a pathologist, from adjacent tissue surround-
ing breast tumors and was isolated as outlined above.
Real-time PCR expression analysis
cDNA was reverse transcribed from 250 ng of RNA using
MMLV-RT and random hexamers as directed (Invitrogen).
cDNA was amplified using the Applied Biosystems Taq-
man Universal PCR Master Mix (no UNG) (cat#
4324018), 8 µl of diluted cDNA (1 µl of cDNA + 7 µl of
ddH20), 1 µl of 20 × Assay on Demand gene expression
assay mix (HPRT1 control primer/probe mix) and 1 µl of
20 × Assay on Demand gene expression assay mix (test
primer/probe mix- catalogue numbers are listed below).
Thermal cycling consisted of a hold at 95°C for 10 min-
utes followed by 40 cycles of 95°C for 15 seconds and
60°C for 60 seconds, using the ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems (ABI)).
Standard curves of serial dilutions ranging from 3 × to
0.005 × of a pool of cDNA were used for quantification,
and slopes generated by the standard curves ranged from
3.3 to 3.6. Test probes were conjugated to the FAM™ fluor
(Applied Biosystems), and the HPRT1 endogenous con-
trol probe was conjugated to the VIC™ fluor (Applied Bio-
systems). The HPRT-1 internal control, which has been
determined by our lab and others to have little variation
between breast tumors [16,17], was chosen to normalize
for variations in mRNA amount and quality between
tumors. We compared the expression levels of the genes to
that of the HPRT-1 housekeeping gene for each sample,
and all mRNA/HPRT-1 expression levels were approxi-
mately one when comparing a pool of cell line cDNA for
each experiment to prevent variation between experi-
ments. For our purposes, mRNA/HPRT-1 ratios of less
than 0.5 × the mean level of expression were considered
to be under-expressed, while mRNA/HPRT-1 ratios of
greater than 2 × the mean level of expression were consid-
ered to be over-expressed. The test and control probes
were multiplexed, and analysis was performed on ratios of
the test quantity mean values to control quantity mean
values for each sample. ABI SDS2.1 software was used to
analyze the results. The primer/probe pairs used for the
experiments were purchased from ABI (cat#: PP1α:
Hs00267568-m1,  PP1β: Hs00160343-m1, PP1γ:
Hs00160351-m1,  BRCA1: HS 00173233-m1, HPRT-1:
4326321E_(endogenous control)).
Statistical analysis of tumor characteristics and their 
association with PP1α and PP1β expression
A descriptive analysis was performed, comparing fre-
quency distributions of tumor characteristics between PP1
groups ('high': greater than 2.2 or 'low': less than or equal
to 2.2), using contingency tables. The median level of
expression of PP1α, in all tumors analyzed (familial (not
shown) and sporadic), was used to establish the level for
high vs. low PP1 expression. Association of each charac-
teristic with PP1 expression was investigated by Fisher's
exact test [18].
All statistical analyses were performed using SAS statistical
software, version 8.2 (SAS Inc., Cary, NC, USA). p < 0.05
was considered to be statistically significant.
Cell culture conditions and transfections
Transfections were performed using Fugene transfection
reagent (Roche) according to manufacturer's directions.
HEK293T cells were acquired from the American Type Tis-
sue Collection and were grown under their recommended
conditions.
Results
Association of BRCA1 with PP1 in vitro
We performed a yeast two-hybrid assay to identify pro-
teins that interact with exon11 of BRCA1. In this study, 9
putative positives were identified including PP1β, an iso-
form of the serine/threonine phosphatase PP1 (not
shown). These initial yeast two-hybrid studies led to fur-
ther examination on the interaction of BRCA1 with PP1β.
Overlapping fragments of BRCA1 (Figure 1A) were cre-
ated to identify the region of BRCA1 required to interact
with PP1 and we determined that BR-4 (amino acids 758
to 1064) mediated the interaction with PP1 (Figure 1B).
Sequence analysis of the BR-4 fragment identified a puta-
tive PP1 interacting domain, (K/R)/(V/I)/XF [19,20],
which is present in several regulatory proteins that interact
with PP1. Similarly to other PP1 interacting domainsBMC Cancer 2007, 7:85 http://www.biomedcentral.com/1471-2407/7/85
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[19,21], there are 2 positively charged amino acids
upstream (893KK894), and a group of negatively charged
amino acids downstream (902ECEQKEE908) of the BRCA1
KVTF sequence, further supporting its classification as a
putative PP1 interacting domain.
Mutation of the valine to alanine, or phenylalanine to
alanine, within the (K/R)/(V/I)/XF PP1 binding domain,
has been shown to affect the binding of PP1 with other
interacting proteins [22]. When BR-4 containing a V-A or
F-A alteration was analyzed for its ability to interact with
PP1, a significant decrease was observed in the amount of
PP1 that interacted with the BR-4 V-A or F-A GST fusion
protein compared to the wild type BR-4 fragment (Figure
1C), indicating that this sequence is required to mediate
the interaction between BRCA1 and PP1.
Association of BRCA1 and PP1 in vivo
To establish that the association between BRCA1 and PP1
is a physiological interaction, HEK293T cells were trans-
fected with Flag-epitope tagged PP1 α, β or γ or pFLAG
Laf4 [11]. Laf4 was chosen as a negative control since it is
expressed in the nucleus, but was not anticipated to inter-
act with BRCA1. We hypothesized that, although BRCA1
GST-pull down assay to identify the region of BRCA1 interacting with PP1 Figure 1
GST-pull down assay to identify the region of BRCA1 interacting with PP1. (A) Fragments used in GST pull down 
assays (BR 2 to 5) are diagrammed. (B) Gel depicting co-precipitation of GST-bound BR-4 with PP1. Following incubation of 
GST-BRCA1 proteins with equal amounts of cell lysate, a western blot was performed and probed with an antibody to the cat-
alytic region of PP1. (C) Analysis of the effect of mutations of the KVTF PP1 interacting domain on the BRCA1- PP1 interac-
tion. GST-bound-BR4 V-A and GST-bound-BR4 F-A binds PP1 with decreased intensity, compared to WT GST-bound-BR4.
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was shown to interact with PP1β in the two-hybrid screen,
it might be capable of interacting with all three PP1 iso-
forms PP1 due to their high degree of sequence similarity.
Protein was immunoprecipitated using antibodies against
BRCA1, or an antibody against the Flag epitope to immu-
noprecipitate Flag epitope tagged PP1α, β, or γ. BRCA1
coimmunoprecipitated all three PP1 isoforms, and con-
versely, PP1 α,  β and γ coimmunoprecipitated BRCA1
(Figure 2), indicating that the interaction between BRCA1
and PP1 is specific.
Analysis of the expression of PP1α, β and γ, and genes 
encoding other BRCA1 associated proteins in breast 
tumors
Our investigations into the interaction of BRCA1 with PP1
led us to examine the expression levels of BRCA1, PP1α, β
and γ in primary human breast tumors. We determined
that the expression levels of PP1α and β were variable in
breast tumors, with several tumors exhibiting very low or
high expression, relative to the mean level of expression
observed for these genes (Table 1). In contrast, PP1γ levels
were less variable, with most tumors exhibiting expression
levels that were not notably outside the mean level of
PP1γ expression. Interestingly, when analyzing levels of
PP1α,  β and γ in normal breast tissue (Table 2), we
observed that levels of PP1β and γ were significantly
higher in normal tissue specimens (PP1β: p = 0.03, PP1γ,
p = 1.9 × 10-6) compared to sporadic breast tumor sam-
ples. A similar trend for decreased PP1α expression was
also observed, although significance was not reached for
this isoform.
BRCA1 has previously been reported to have a decreased
level of expression in tumors, relative to normal breast tis-
sue [2]. We also observed that 28% of the tumors we ana-
lyzed had low levels of BRCA1, and 8% of those tumors
had extremely low to non-detectable levels of BRCA1
expression. Not surprisingly, BRCA1 expression levels in
normal breast tissue were significantly higher those seen
in sporadic breast tumors (p = 0.01).
Tumor characteristics and association with PP1α 
expression
To identify an association with the characteristics of the
breast cancer cases used in this study and their level of
PP1α and β expression, contingency-table Fisher's exact
tests were performed. The group of breast tumors with a
Coimmunoprecipitation of BRCA1 and PP1 Figure 2
Coimmunoprecipitation of BRCA1 and PP1. HEK293T kidney cells were transfected with vectors encoding untagged 
BRCA1 under the control of a CMV promoter, and vectors encoding Flag-PP1α, β, γ or Flag-Laf4. (A) A western blot probed 
with BRCA1 shows that immunoprecipitation of protein with an antibody against the Flag-PP1α, β or γ proteins, but not Laf4, 
co-immunoprecipitates BRCA1 (Lanes 1A-1D). It should be noted that the band observed slightly lower than BRCA1 in lane 
1D is a non-specific background band. Lanes 1E-1H show immunoprecipitation of BRCA1 using antibodies against the amino 
and carboxy termini of BRCA1. (B) A western blot probed with an antibody against the Flag epitope. Lanes 2A-2D indicate 
immunoprecipitation of the Flag-epitope tagged PP1α, β or γ or Flag-Laf4. Lanes 2E-2G show co-immunoprecipitation of Flag-
PP1α, β or γ with antibodies against BRCA1, and lane 2H shows a lack of coimmunoprecipitation of the negative control Flag-
Laf4 by BRCA1.
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'low' level of PP1α mRNA was compared to those with
'high'  PP1α expression. Although no correlations were
observed in age, menopausal status, tumor size, histologic
grade, PgR status and lymphatic invasion, we did detect an
association between low PP1α expression and ER status (p
= 0.02). Tumors with 'low' PP1α levels were more likely to
be negative for ER receptor than those with 'high' PP1α
levels (87% vs. 25%). No correlations were observed
between 'high' or 'low' PP1β expression and any of the
tumor characteristics outlined above.
Discussion
BRCA1 interacts with a large number of proteins, and may
function as a scaffold protein to bring cell cycle or DNA
repair processes together, but the mechanisms by which
BRCA1 functions in these processes have yet to be fully
elucidated. We performed a yeast two-hybrid study to
identify proteins that interact with exon11 of BRCA1. The
region of BRCA1 encoded by exon 11 is known to interact
with a number of proteins involved in DNA repair [23], as
well as γ-tubulin [3] and several kinases including Aurora-
A kinase [24] and ChkII [25]. Identification of additional
interacting partners, particularly ones that could modify
the activity of a BRCA1 through changes in phosphoryla-
tion, may further aid in clarifying its function and regula-
tion. In this yeast two-hybrid study, we identified the
serine/threonine phosphatase PP1β as a BRCA1 interact-
ing protein, which could have important consequences on
both the activity of BRCA1 and the regulation of PP1β
activity.
PP1 has 3 isoforms encoded by different genes that are
97% conserved across their catalytic domains and distinct
roles for each isoform have yet to be determined. When
we coimmunoprecipitated Flag-epitope tagged PP1α, β or
γ with BRCA1, we observed that all 3 isoforms interacted
with BRCA1. Additionally, we have identified the func-
tional PP1 interacting domain within BRCA1. This
domain is found in other PP1 regulatory proteins, sug-
gesting that BRCA1 may regulate the activity of PP1 and
could act as a scaffold protein to promote the dephospho-
rylation of BRCA1 associated proteins by PP1.
The expression levels of BRCA1 and the PP1 isoforms were
analyzed in primary human breast tumors. Low levels of
BRCA1 mRNA were identified, consistent with decreased
expression rather than mutation as a method for BRCA1
inactivation in these tumors. Additionally, we observed
variable levels of expression for PP1α and β, but not PP1γ.
Interestingly, decreased levels of PP1β and γ were identi-
fied when comparing their gene expression levels from
normal breast tissue with expression levels from sporadic
breast tumors (Table 2). This decreased expression may
lead to perturbations of PP1 protein levels, altering the
balance of kinase and phosphatase activities acting on
specific substrates and potentially disrupting important
cellular functions.
The use of primary human breast tumors allowed us to
examine correlations between tumor and patient charac-
teristics with PP1α or β expression. Interestingly, we
Table 1: Distribution of gene expression in Primary Sporadic Human Breast Tumors
Gene Name Number of Tumors (N) Mean expression level (M) N < 0.5 × M N > 2 × M
PP1α  24 3.1 4 (17%) 2 (8.4%)
PP1β  26 2.8 5 (19 %) 5 (19 %)
PP1γ  23 1.3 1 (4.3%) 1 (4.3%)
BRCA1 25 0.6 7 (28%) 2 (8%)
1test gene/HPRT-1 expression ratios as measured by quantitative real-time PCR
Table 2: Gene Expression Levels in Normal Breast Tissue Compared to Sporadic Breast Tumors
Name of Gene Tissue Type Mean Expression Level1 Significance (p)
BRCA1 Normal 0.9 0.01
Sporadic 0.6
PP1α  Normal 3.6 0.29
Sporadic 3.1
PP1β  Normal 3.9 0.03
Sporadic 2.8
PP1γ  Normal 3.2 1.9 × 10-6
Sporadic 1.3
1. mRNA/HPRT-1 expression ratios as measured by quantitative real-time PCR, relative to the pool of cDNABMC Cancer 2007, 7:85 http://www.biomedcentral.com/1471-2407/7/85
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observed a statistically significant association between the
level of PP1α expression and estrogen receptor (ER) status
using our small sample of 24 sporadic tumors, which will
need to be investigated further in a larger sample set. ER
turnover is affected by a basal level of phosphorylation
that is maintained through a balance of kinase and phos-
phatase activities [26]. Activation of protein phosphatase
PP2A has recently been shown to increase the level of ER
mRNA stability [27]. Our results indicate that tumors with
low expression of PP1α are more likely to be ER negative
than tumors with high expression of PP1α (87% vs. 25%)
and it is possible that PP1α has a role in ER mRNA stabil-
ity, similarly to that of PP2A.
Conclusion
We have characterized the interaction of PP1 with BRCA1
and have identified a PP1 binding domain within BRCA1
that is necessary for this interaction to occur. Furthermore,
expression of the PP1 isoforms as well as several genes
encoding BRCA1 interacting proteins was analyzed in pri-
mary human invasive breast tumors. We detected low lev-
els of BRCA1 expression in 28% of tumors, respectively,
and variable levels of PP1α and β. Moreover, significant
decreases in expression were observed for BRCA1, PP1β
and PP1γ when comparing normal breast tissue with inva-
sive breast cancers. Additionally, a significant association
of PP1α levels with ER status in breast tumors was identi-
fied that could lead to additional studies into the effect of
PP1α on ER mRNA stability and its role in the develop-
ment of breast cancer. The studies presented here provide
evidence for an important role for PP1 in the develop-
ment of breast cancer, possibly through its association
with BRCA1, and suggest that deregulation of the balance
of kinase and phosphatase activity in the cell may be an
important component of breast tumorigenesis.
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